THYROID CANCERS

Can ALK inhibitors have the same impact on other malignancies that harbor ALK rearrangements as is has on non–small cell lung cancer?

Eric Nadler, MD, MPP, led a Case-Based Roundtable discussion on treating a 58-year-old man with thyroid cancer.

Lori Wirth, MD, discusses the future of selpercatinib in RET-altered thyroid cancers. 

In medullary thyroid cancer, older patients are more likely to have more aggressive disease and disease specific mortality.

Twelve months after a male patient with RET-mutant thyroid cancer was no longer asymptomatic, the patient developed symptoms that led the treating physician to discover metastatic disease.

Progression-free survival was significantly prolonged with cabozantinib as treatment of patients with radioiodine-refractory differentiated thyroid cancer in the phase 3 COSMIC-311 clinical trial, showing potential as a new treatment option and leading to the filing of a application for FDA approval.

During a Targeted Oncology Case-Based Roundtable event, Krzysztof Misiukiewicz, MD, discussed the case of a 58-year-old patient with RET-mutated thyroid cancer

A non-randomized, open-label trial of AIC100, an autologous chimeric antigen receptor T-cell agent for the treatment of relapsed/refractory thyroid cancer, is currently recruiting patients at the Weill Cornell Medical College in New York, under the supervision of Koen van Besien, MD, PhD.

During a Targeted Oncology Case-Based Roundtable event, Guilherme Rabinowits, MD, discussed the case of a 58-year-old patient with medullary thyroid cancer.

Erminia Massarelli, MD, PhD, MS, discussed the case of a 58-year-old man with RET-mutant medullary thyroid cancer.

Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.

The 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer expand on discussions about treatment goals and palliative care.

Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.

Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.

An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.

Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.

Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.

Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.

Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.

Pediatric patients with advanced RET-altered solid tumors showed preliminary efficacy with selpercatinib, according to data presented at the 2021 ASCO Annual Meeting.

Updated findings show how selpercatinib improves responses in patients with RET-mutant medullary thyroid cancer regardless of the prior treatment they had.

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.

Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.

The FDA has granted a fast track designation to the autologous chimeric antigen receptor T-cell agent, AIC100, for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

Overall survival was prolonged in patients with radioactive iodine-refractory differentiated thyroid cancer and lung metastases larger than 1 cm who were treated with lenvatinib in the SELECT study.

The DECISION and SELECT studies provide evidence of response to multikinase inhibitors after disease progression in patients with thyroid carcinoma.

Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors.

In an interview with Targeted Oncology, Vivek Subbiah, MD, reviewed the data supporting selpercatinib as treatment of RET fusion-positive thyroid cancers, as well as the exploration of this agent in other RET-altered cancers.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, discussed the case of a 58-year-old patients with RET-mutated thyroid cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Lori Wirth, MD, discussed the treatment patients with radioiodine-refractory differentiated thyroid cancer with a group of peers.